Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair
Launched by UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE · Apr 29, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a specific pain management technique called a Quadratus Lumborum (QL) block can help reduce the amount of opioid pain medication needed after ventral hernia surgery compared to a placebo, which is a substance that doesn't contain any active medication. The goal is to see if using this technique not only helps with pain relief in the first 24 hours after surgery but also supports a better recovery overall.
To be eligible for this study, participants should be at least 18 years old, able to understand the study procedures, and willing to sign a consent form. They must be undergoing elective open surgery for a ventral hernia and will receive a mesh implant during the procedure. Participants will complete a questionnaire before the surgery and another one at a follow-up visit about 30 days later. Additionally, they'll keep a pain diary for the first day after surgery, and the study will collect information about pain levels, medications used, hospital stay, and any complications. This research aims to improve pain management and recovery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. \>18 years of age
- • 2. Able to read and understand study procedures
- • 3. Willing to participate and sign an informed consent form
- • 4. Open approaches to ventral hernia repair
- • 5. Clean (CDC Class I), clean-contaminated (CDC Class II)
- • 6. Elective surgery
- • 7. Mesh placed in the retromuscular position
- Exclusion Criteria:
- • 1. Dirty-Infected cases (CDC Class IV): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera
- • 2. Patient has a contraindication to receiving the drug and/or procedure: allergy/sensitivity to the drug, coagulopathy, abdominal wall infection at the drug administration site, systemic infection, anatomical distortion, neuropathy
- • 3. Emergent procedure
- • 4. Mesh not placed
About University Of Tennessee Graduate School Of Medicine
The University of Tennessee Graduate School of Medicine is a leading academic institution committed to advancing medical education, research, and clinical practice. With a focus on innovative healthcare solutions and improving patient outcomes, the institution conducts clinical trials that explore new therapeutic approaches and enhance medical knowledge. Collaborating with a diverse network of healthcare professionals and researchers, the Graduate School of Medicine aims to foster a culture of inquiry and excellence, contributing to the development of evidence-based practices in various medical fields. Through its dedicated efforts, the University of Tennessee Graduate School of Medicine plays a pivotal role in shaping the future of medicine and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Knoxville, Tennessee, United States
Patients applied
Trial Officials
Kaela E Blake, MD
Principal Investigator
The University of Tennessee Graduate School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported